LATTE Summary for Health Professionals

Breast cancer survival has been improving for the past 20 years and is increasingly becoming a “survivable” disease which indicates that a risk-benefit analysis of treatment requires a careful evaluation of long term effects. Good information is available about long term survival through the efforts of the Early Breast Cancer Trialists’ Collaborative Group located in Oxford, but these data are based on women diagnosed and treated before the advent of aromatase inhibitors (AIs).

The ATAC trial is the vanguard breast cancer trial for the use of AIs in the adjuvant setting, with a median follow-up of 10 years, and has already produced practice changing data for post - menopausal women with hormone sensitive breast cancer. For the first time, we have an opportunity on the long-term efficacy and safety of an aromatase inhibitor.

The last patients attended their final follow-up for the ATAC trial in March 2009 which highlights the need to address these long term questions now with the LATTE study.

This research will aim to provide additional efficacy data; time to recurrence of breast cancer in the post 10 year period and death after recurrence, as well as additional safety data; other primary cancers, serious fractures and cardiovascular events. The data collected in LATTE will remain unblinded as much as possible throughout the duration of the study.

The UK, which was the largest single contributor of patients to the ATAC trial, is hosting the co-ordinating centre at Queen Mary, University of London (Principal Investigator: Professor Jack Cuzick) in liaison with the Clinical Trials Group at UCL.

Link to website: